Pfizer
NEWS
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NASH, because it has several components.
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
As part of a plan to lower prescription drug prices for millions of Americans, President Donald Trump is set to announce a sweeping plan to overhaul how Medicare pays for medication.
Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.
John D. Arnold, a billionaire hedge fund manager who made his fortune on energy stocks, is now taking on the cost of high prescription drugs. The Texas-based Arnold has spent more than $100 million on health-related grants since 2014, with a significant portion dedicated to cheaper medications.
Pharma giant Pfizer and Bain Capital teamed up to launch Cerevel Therapeutics, a new biopharmaceutical company based in Boston that will focus on developing therapies to treat central nervous system disorders.
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
JOBS
IN THE PRESS